Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
06/10/2019 06/11/2019 06/12/2019 06/13/2019 06/14/2019 Date
1577(c) 1573.8(c) 1583.2(c) 1582.6(c) 1584.4(c) Last
4 952 129 5 828 731 5 237 850 6 301 783 5 843 672 Volume
+0.75% -0.20% +0.60% -0.04% +0.11% Change
More quotes
Financials (GBP)
Sales 2019 31 784 M
EBIT 2019 8 264 M
Net income 2019 4 232 M
Debt 2019 24 166 M
Yield 2019 5,11%
Sales 2020 34 285 M
EBIT 2020 8 953 M
Net income 2020 4 629 M
Debt 2020 22 200 M
Yield 2020 5,11%
P/E ratio 2019 18,21
P/E ratio 2020 17,89
EV / Sales2019 3,22x
EV / Sales2020 2,92x
Capitalization 78 072 M
More Financials
Company
GlaxoSmithkline is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (56%): intended for respiratory diseases (40.1% of net sales), HIV infection (27.3%), immune system disorders (2.7%) ) and other (29,8%); - OTC and... 
Sector
Pharmaceuticals
Calendar
07/24Earnings Release
More about the company
Surperformance© ratings of GlaxoSmithKline
Trading Rating : Investor Rating :
More Ratings
Latest news on GLAXOSMITHKLINE
06/14GLAXOSMITHKLINE : Board Meeting other than Financial Result of GlaxoSmithKline C..
AQ
06/14Morphic Holding Sets IPO at 5 Million Shares; Sees Pricing at $14-$16 Apiece
DJ
06/14GLAXOSMITHKLINE : taps UCs CRISPR expertise to speed drug discovery
AQ
06/13GSK signs up gene-editing pioneers in drug discovery alliance
RE
06/11Seattle Genetics' Antibody-Drug Conjugate Technology Utilized in Genentech's ..
AQ
06/10GLAXOSMITHKLINE : Glaxo sells brands including Savlon antiseptic cream to Hudder..
AQ
06/08GLAXOSMITHKLINE : US approves self administration for GlaxoSmithKline asthma dru..
AQ
06/07Germany's Stada buys six of GSK's consumer brands, eyes further deals
RE
06/07GLAXOSMITHKLINE : FDA approval for Nucala self-administration
PU
06/06GLAXOSMITHKLINE : Nucala (mepolizumab) Gains FDA Approval for Two New Self-Admin..
BU
More news
Analyst Recommendations on GLAXOSMITHKLINE
More recommendations
Sector news : Pharmaceuticals - NEC
02:48aDrug Firms Sue Over Ad Rule -- WSJ
DJ
06/14Drugmakers Sue to Block Federal Rule Requiring Drug Prices in TV Ads
DJ
06/14BAYER : to Invest Billions in Weedkillers in Wake of Roundup Controversy--Update
DJ
06/14BAYER : Deutsche Bahn to Phase out Glyphosate -WirtschaftWoche
DJ
06/14BAYER : to Invest Billions in Weedkillers in Wake of Roundup Controversy
DJ
More sector news : Pharmaceuticals - NEC
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 20
Average target price 16,4  GBP
Spread / Average Target 4,8%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Philip Roy Hampton Non-Executive Chairman
Simon Paul Dingemans Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE6.25%97 904
JOHNSON & JOHNSON9.04%348 981
PFIZER-2.63%233 072
ROCHE HOLDING LTD.13.39%227 848
NOVARTIS20.35%220 893
MERCK AND COMPANY8.34%206 641